

CURRICULUM VITAE
GREGORY CHENG MD PhD

NAME: Dr. Gregory Cheng
DATE OF BIRTH: 26 October 1954
PLACE OF BIRTH: Hong Kong
LANGUAGE : Chinese, English

DEGREES AND SPECIALTY CERTIFICATIONS

MD	University of Toronto	Jun 1978
FRCP (Canada)	Internal Medicine	May 1982
FRCP (Canada)	Hematology	Nov 1984
FRCP (Canada)	Medical Oncology	Nov 1985
American Board	Internal Medicine	Nov 1981
American Board	Oncology	Nov 1983
American Board	Hematology	Nov 1984
PhD	Institute of Medical Science	Jun 1990
	University of Toronto	
Fellow	Hong Kong College of Pathologists	Dec 1993
Fellow	HK Academy of Medicine (Pathology)	Dec 1993
Fellow	Hong Kong College of Physician	Dec 1997
Fellow	Hong Kong Academy of Medicine (Internal Medicine)	Dec 1997

HONOURS AND AWARDS

Medical Research Council Fellowship	1985-89
Terry Fox Fellowship	1983-85
Doctor of Medicine (Honours)	1978
Ontario Heart Foundation (Summer Scholarship)	1976
Medical Research Council (Summer Scholarship)	1975
Thomas Kirby Scholarship (U of Toronto)	1972-74
Awarded Best Teacher for Year 3 (CUHK)	2002, 2004, 2005, 2011
Awarded Best Teacher for Year 5 (CUHK)	2000, 2001, 2002, 2004, 2005
Vice-Chancellor s Exemplary Teaching Award (CUHK)	2001, 2005
Master Teacher (CUHK)*	2005

* Master Teacher is awarded to teaching staff who has won the Best Teacher of the Year Award for five times. Once awarded the Master Teacher, the teaching staff will not be eligible for the Best Teacher of the Year Award for at least five years.

WORKING EXPERIENCE

Haematology Consultant	Peel Memorial Hospital, Toronto	1987-89
Oncology Consultant	Peel Memorial Hospital, Toronto	1987-89
Deputy Director	Ottawa Red Cross	1989-91
Haematology Oncology Consultant	Ottawa General Hospital	1989-91 & 1992-93
Assistant Professor	University of Ottawa	1989-91
Senior Clinical Pathologist I/C of QMH Blood Bank	Queen Mary Hospital, HK	1992-96
Honorary Clinical Lecturer	University of Hong Kong	1992-present
Chairman	HK Blood Transfusion Society	1994-1995
Honorary Lecturer	University of Hong Kong (Sch of Prof & Cont Edu)	1995-present
Professor	Faculty of Medicine, CUHK	1997-2010
Council Member	HK Association of Blood Transfusion & Haematology	1997-present

CURRENT POSITION:

Consultant Hematologist-Oncologist

澳門科大醫院, University Hospital, Macau University of Science & Technology

Adjunct Distinguished Professor, Faculty of Health Science,
Macau University

Director, Humanity and Health Clinical Trial Center

PUBLICATIONS:

1. A.C. Bested, **G. Cheng**, P.H. Pinkerton, O. Kassim, J.S. Senn. Idiopathic acquired sideroblastic anaemia transforming to acute myelosclerosis. *J. Clin. Pathol.* 1984; 37:1032-1034.
2. J.S. Senn, D.W. Stoneman, **G. Cheng**, E.E. Kassel, J.H.P. Main. Multiple myeloma with initial presentation in the jaw: a clinical-pathologic discussion. *J. of Oral Pathol.* 1985; 14:282-288.
3. **G. Cheng**, D. Tritchler, J.E. Curtis, E.A. McCulloch. In Vitro Sensitivity of AML Blast Progenitor Cells to Hydrocortisone. *Leukemia Res.* 1985; 9:1547-1557.
4. **G. Cheng**, M.D. Minden, T. Mak, E.A. McCulloch. Rearrangement of T-cell Receptor and Immunoglobulin genes in AML-An aspect of lineage infidelity. *J. Exp. Med.* 1986; 163:414.
5. E.A. McCulloch, M.D. Minden, C. Kelleher, J. Miyauchi, C. Wang, **G. Cheng**. Genetically Determined Regulators Acting on the Blast Cells of Acute Myeloblastic Leukemia. *Hemato-Oncology and Hemato-Immunology. Proc. 2nds Conf. Catania 1986. Acta Haemat.* 1987; 78 suppl. 1:18-25.
6. **G. Cheng**, C.A. Kelleher, J. Miyauchi, C. Wang, G. Wong, S.C. Clark, E.A. McCulloch, M.D. Minden. Structure and Expression of Genes of GM-CSF and G-CSF in Blast Cells from Patients with Acute Myeloblastic Leukemia. *Blood* 1988; 71; 1:204-208.
7. C. Wang, C.A. Kelleher, **G. Cheng**, J. Miyauchi, G.G. Wong, S. Clark, M. Minden, E.A. McCulloch. Expression of the CSF-1 Gene in the Blast Cells of Acute Myeloblastic Leukemia Association with Reduced Growth Capacity. *Journal of Cellular Physiology* 1988; 135:133-138.
8. E.A. McCulloch, C.A. Kelleher, J. Miyauchi, C. Wang, **G. Cheng**, M.D. Minden, J.E. Curtis. Heterogeneity in Acute Myeloblastic Leukemia. *Leukemia* 1988; Suppl 2:38-49.
9. Y.S. Li, B. Luke, H.S. Wang, M.T. Aye, **G. Cheng**. Deletion of One GM-CSF Allele and Rearrangement of the Other in a Patient with Myelodysplastic Syndrome: Possible loss of Function of a Tumor Suppressor Gene Closely Linked to the GM-CSF Locus on Chromosome 5. *British J. of Hematology* 1991(Sept):121.
10. Giulivi, M.T. Aye, P. Gill, **G. Cheng**. Anti-HCV Screening at a Canadian Red Cross Centre: Significance of a Positive HCV C-100 ELISA Screening Test. *Transfusion* 1992; 32:309.
11. YS Li, HS Wong, B Luke, **G Cheng**, MT Aye. Cytogenetic studies using frozen sample. *Cancer Genet Cytogenet* 1992; 59:99-100.
12. M.T. Aye, S. Hashemi, B. Leclair, A. Zeibdawi, E. Trudel, M. Halpenny, V. Fuller, **G. Cheng**.

Expression of Stem Cell Factor and c-kit mRNA in Cultured Endothelial Cells, Monocytes and Cloned Human Bone Marrow Stromal Cells (CFU-RF). *Journal of Experimental Haematology* 1992; 20:523.

13. **G. Cheng**, W. McLeish, L. Huebsch, J. Drouin, R. van der Jagt, P. Tittley, S. Markman, M.T. Aye, B. Burns. Rearrangements of BCR Genes in Malignant Lymphoma. *Leukemia* 1992; 6:553.
14. **G. Cheng**, S.Y. Ha, H.W. Liu, Y.L. Kwong, L.C. Chan, C.K. Li. A patient with marked leucocytosis, t (8, 21), absent Philadelphia chromosome, but rearranged BCR gene. *British Journal of Haem.* 1992; 82(1):171-172.
15. **G. Cheng**, R. van der Jagt, J. Drouin, L. Huebsch, B. McLeish, P. Tittley, J.M. Trempe. Occurrence of T-cell Lymphoma in a Patient with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia with Rearrangement of BCR and TCR- Genes in the Lymph Node. *American Journal of Hematology* 1993(Sept):229.
16. R. Liang, **G. Cheng**, M.S. Wat, S.Y. Ha, L.C. Chan. Childhood acute lymphoblastic leukaemia presenting with relapsing hypoplastic anaemia: progression of the same abnormal clone. *Br. J. of Haem.* 1993; 83:340-342.
17. Y.L. Kwong, **G. Cheng**. Clonal Nature of Chronic Neutrophilic Leukemia. *Blood* 1993(August); 82:1035-1036.
18. **G. Cheng**, C. Kumana, C.L. Lai, R. Lo. Audit of use of synthetic colloids and blood alternatives in Hospitals. *Journal of HKMA*, 1993(Sept); 45:3.
19. Y.L. Kwong, **G. Cheng**, T.S. Tang, E.P. Robertson, C.P. Lee, L.C. Chan. Transient myeloproliferative disorder in a Down's neonate with rearranged T cell receptor gene and evidence of in vivo maturation demonstrated by dual colour flow cytometric DNA ploidy analysis. *Leukaemia* 1994; 7:1667-1671.
20. **G. Cheng**. Guidelines for the use of fresh-frozen plasma, cryoprecipitate, and platelets. *JAMA* 1994(Nov):7-8.
21. **G. Cheng**, A. Chan, M. Chun, L. Wong. Evaluation of the gel test for antibody screening in a tertiary Hospital in Hong Kong; insensitivity for some cold antibodies that are reactive at 37° by conventional indirect antiglobulin tests. *Clin. Lab Haem.* 1995; 17(1):81-84.
22. **G. Cheng**, L. Wong. Review of the Type and Screen system implemented in Queen Mary Hospital. *The Hong Kong Medical Association* 1995(Mar); 1(1):27-30.
23. **G. Cheng**, C.H. Hui, S.Y. Ha, C.K. Lam, L. Wong, K.H. Mak, C.K. Lin. Haemolytic transfusion reactions due to Mi-antibodies; need to include MiltenbergerIII positive cells in pre-transfusion antibody screening in Hong Kong. *Clin. Lab. Haem.* 1995; 17(2):183-184.
24. K.H. Mak, C.K. Lin, D.S. Ford, **G. Cheng**, C. Yuen. The first example of anti-Gy^a detected in

Hong Kong. *Immunohematology* 1995; 11(1):20-21.

25. **G. Cheng.** Severe ABO hemolytic disease of newborn is infrequent among Hong Kong Chinese. *Vox Sang* 1996; 70(1):45.
26. **G. Cheng, F. Choi, L Wong.** Failure to detect potent Anti-H in parabombay patients with the gel system. *Clinical and Laboratory Haematology* 1996; 18(1):64.
27. **G. Cheng, D.S.M. Chiu, A.S.M. Chung, et al.** A novel system for providing compatible blood to patients during Surgery -
1996; 36(4):347-350.
28. **G. Cheng, H.F. Wong, A. Chan, C.H. Chui.** The effects of a self-educating blood component request form and enforcements of transfusion guidelines on FFP and platelet usage. *Clinical and Laboratory Haematology* 1996; 18(2):83-87.
29. **G. Cheng, A.H.C. Chan, H.F. Wong, C.H. Chui, L.Y.F. Wong.** The impact of gel test on routine work in a general hospital blood bank. *Immunohematology* 1996; 12(1):30-32.
30. A.H.C. Chan, J.C.M. Chan, L.Y.F. Wong, **G. Cheng.** From maximum surgical blood ordering schedule to unlimited computer crossmatching - evolution of blood transfusion for surgical patients at a tertiary hospital in Hong Kong. *Transfusion Medicine* 1996; 6:121-124.
31. **G. Cheng, C.H. Chui, K.L. Au Yeung, E.O.T. Kan, S.Y. Wong, K.O. Yee, S.C. Yip, M.N. Leung, H.K.K. Fung, T.C.W. Fan.** Provision of an out-of-hours blood banking service at a satellite hospital without blood bank staff. *Clin. Lab. Haem.* 1996; 18.
32. HY Chan, SY Ha, ACW Lee, CF Chan, **G Cheng,** YL Lau. Autologous Transfusion for Paediatric Marrow Donor. *HKJ Paediatr (new series)* 1996; 1:67-69.
33. CK Lin, KH Mak, CMY Yuen, NK Chan, HW Liu, **G Cheng.** A case of hydrops fetalis, probably due to antibodies directed against antigenic determinants of GP. Mur (Miltenberger class III) cells. *Immunohematology* 1996; 12(3):115-118.
34. CH Chui, FY Lau, AHC Chan, JCO Tang, CH Hui, CCK Lam, LC Chan, **G Cheng.** Expression of an abnormal sized c-kit transcript in Hong Kong Chinese acute lymphoblastic leukaemia patients. *Clin. Lab. Haem.* 1996; 18,261-263.
35. C.H. Chui, F.Y. Lau, K.S. Yau, F.C.P. Lee, L.C. Chan, **G Cheng.** Low frequency of c-kit expression and detection of an aberrant Kit message among Hong Kong Chinese myelogenous leukaemia patients. *Cancer Letters* 1997; Vol 116, 253-258.
36. Chu Pak Lau, Hung Fat Tse, **G. Cheng.** Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients. *Heart* 1997; 78:358-363.
37. **G Cheng,** Pathology Forum; A Lawyer with Dizziness. *The Hong Kong Practitioner*, Vol.19, No. 10,552-553, 1997.

38. Hung-Fat Tse, MB, Chu-Pak Lau, MD, FACC, **Gregory Cheng**, MD, PhD. Relation between Mitral Regurgitation and Platelet Activation. *JACC* Vol. 30, No. 7, December 1997:1813-8.
39. Dr James Ka-Hay Luk, MBBS(HK), Msc, MRCP(UK), **Dr Gregory Cheng**, MD, PhD, FRCP(C), Professor Jean Woo, MD, FRCP, FRACP. Prolonged Activated Partial Thromboplastin Time (APTT) in an 86-year-old Patient. *Journal of the Hong Kong Geriatrics Society*, Vol. 8 No.1 Dec. 1997.
40. CH Chui, PHM Leung, FY Lau, TSK Wan, LC Chan, **G Cheng**. Lack of structural rearrangement in c-kit and stem cell factor genes in Hong Kong Chinese patients with myelodysplastic syndromes or acute myeloid leukaemia. *HKMJ* Vol 4 No. 1 March 1998
41. **G. Cheng**, M Tang, T Lao, KM Mak, CK Lin. An update of the serological characteristics of the Miltenberger antibodies detected among Chinese patients in Hong Kong, together with a discussion on their clinical significance. *Vox Sang* 1998; 74:59-60
42. **G. Cheng**
(Suppl. 2): 427-429. (State of Art Lecture, XXV Congress of the ISBT)
43. F.Y. Lau, Raymond Wong, C.H. Chui, Elaine Ng, **Gregory Cheng**. Improvement in transfusion safety using a specially designed transfusion wristband. *Transfusion Medicine* 2000, 10:121-124.
44. TWT Leung, **G Cheng**, CH Chui, SKW Ho, FY Lau, JKJ Tjong, TCC Poon, JCO Tang, WCP Tse, KF Cheng, YC Kong. Yuehchulcene (abisindole alkaloid) and cyclophosphamide are active in breast cancer in vitro. *Chemotherapy* 2000 Vol 46, 62-68.
45. R Wong, F.Y. Lau, C.H. Chui, K.S. Tsang, K.W. Chik, C.K. Li, **G Cheng**. Transfusion of Peripheral Blood Stem Cells from Donor Homozygous for a Shared HLA-haplotype Avoiding fatal transfusion associated graft-versus-host disease while preserving anti-leukaemic effect. *Transplantation* 2001 Feb 15; 71(3):487-90.
46. FY Lau, Raymond Wong, CH Chui, **G Cheng**. Successful engraftment in two adult patients with severe aplastic anaemia using non-myeloablative conditioning followed by unrelated HLA-mismatched cord blood transplantation. *J Hematother Stem Cell Res.* 2001 Apr; 10(2):309-11.
47. RSM Wong, FY Lau, **G Cheng**. Successful treatment of acquired hypoprothrombinemia without associated lupus anticoagulant using intravenous immunoglobulin. *Haematologica* 2001; 86:551.
48. FY Lau, R Wong, NPH Chan, CH Chui, E Ng, MHL Ng, **G Cheng**. Provision of phenotype-matched blood units-no need for pretransfusion antibody screening. *Haematologica* 2001; 87:742-748.

49. A.M.H. Ho, P. Dion, M.K. Karmakar, **G. Cheng**, J.L. Derrid, D.C. Chung, B.A. Tay. A pharmacokinetic model for factor VIII dosing during active haemorrhage with haemophilia A. *Anesthesia* 2001; 56:785-790.
50. CH Chui, FY Lau, R Wong, OY Soo, CK Lam, P W Lee, HK Leung, CK So, WC Tsoi, N Tang, WK Lam, **G Cheng**. Vitamin B12 Deficiency need for a new guideline. *Nutrition* November 2001.
51. **G Cheng**. To err is human nature. Can transfusion errors due to human factors be reduced? *Clin Chim Acta* November 2001.
52. T Kwok, **G. Cheng**, J Woo, WK Lai, and C.P. Pang. Independent Effect of Vitamin B₁₂ Deficiency on Hematological Status in Older Chinese Vegetarian Women. *American Journal of Hematology* 70:186-190 (2002)

61. Joyce H.S. You, Fredric W.H. Chan, Raymond S.M. Wong, Miranda W.S. Lai, Eva M.W. Chan, **Gregory Cheng**. Outcomes of long-term warfarin therapy under two ambulatory care models in Hong Kong. *Am J Health-Syst Pharm* Vol 60 Aug 15, 2003; 1692-1694.
62. Joyce H.S. You, Fredric W.H. Chan, Raymond S.M. Wong, **Gregory Cheng**. Cost-effectiveness of Two Models of Management of Patients on Chronic Warfarin Therapy A Markov Model Analysis. *Thromb Haemostasis* 2003 Dec; 90(6):1106-11.
63. CH Chui, JCO Tang, FY Lau, ITN TEO, MYC Yau, RSM Wong, **G Cheng**, SKW Ho, TWT Leung, KS Hui, MM Wong, Sarwat fatima, CH Cheng, F Cheung, WQ Tan, LMC Chow, D Gou and ASC Chan. Gleditsia sinensis fruit extract induced growth inhibition involves basic fibroblast growth factor and nitric oxide. *International Journal of Molecular medicine* 13:169-173, 2004.
64. Teo IT, Tang JC, Chui CH, **Cheng GY**, Yau MY, Lau FY, Wong RS, Leung TW, Cheung F, Ho KP, Cheng CH, Chan AS. Superoxide anion is involved in the early apoptosis mediated by Gleditsia sinensis fruit extract. *Int J Mol Med*. 2004 Jun; 13(6):909-13.
65. Y Soo, YF Cheng, R Wong, D Hui, CK Lee, K Tsang, M Ng, WS Wong, P Chan, **G Cheng**, J Sung. Retrospective Comparison of Convalescent plasma with Continuing High Dose Methylprednisolone Treatment in SARS patients. *CMI* 2004 Jul; 10(7):676-8.
66. DS Hui, FW Ko, JP Fok, MC Chan, DK Choy, TS Li, B Tomlinson, **G Cheng**. The Effects of

72. Yunfeng Cheng, Raymond Wong, Yannie OY Soo, WS Wong, CK Lee, Margaret HL Ng, Paul Chan, KC Wong, CB Leung, **Gregory Cheng**. Use of Convalescent Plasma Therapy in SARS patients in Hong Kong. *EUR J Clin. Microbiol Infect Dis*. 2005 Jan; 24(1):44-6.
73. Yunfeng Cheng, **Gregory Cheng**, CH Chui, FY Lau, Paul KS Chan, Margaret HL Ng, Joseph JY Sung, Raymond SM Wong. ABO Blood Group and Human Susceptibility to SARS. *JAMA* Vol. 293, no. 12:1450-51, Mar 2005.
74. CH Chui, Denise FY Lau, Albert SC Chan, **Gregory YM Cheng**, Raymond SM Wong, KB Lai, Stanton HL Kok, Terry TL Au Yeung, Ivy TN Teo, Mable YC Yau, Filly Cheung, CH Cheng and Johnny Cheuk On Tang. Gleditsia sinensis fruit extract induced apoptosis involves changes of reactive oxygen species level, mitochondrial membrane depolarization and caspase 3 activation. *Int J Mol Med*, 2005 Mar; 15(3):539-43.
75. Joyce H.S., Fredric W.H. Chan, Raymond S.M. Wong, **Gregory Cheng**. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? *Br. J Clin Pharmacol*. 59:5; 582-587, May 05.
76. Chui CH, Lau FY, Tang JC, Kan KL, Cheng GYM, Wong RS, Kok SH, Lai PB, Ho R, Gambari R, Chan AS. Activities of fresh juice of *Scutellaria barbata* and warmed water extract of *Radix Sophorae Tonkinensis* on anti-proliferation and apoptosis of human cancer cell lines. *Int J Mol Med*. 2005 Aug; 16(2):337-41.
77. Vivian Lee, Joyce H.S. You, Kenneth K.C. Lee, T.S. Chau, Mary M.Y. Waye, Gregory Cheng. Factors Affecting the Maintenance Stable Warfarin Dosage in Hong Kong Chinese Patients. *Journal of Thrombosis and Thrombolysis* 2005 Aug; 20(1):33-38.
78. Chui CH, Gambari R, Lau FY, Teo ITN, Ho KP, Cheng GYM, Ke B, Higa T, Kok SHL, Chan ASC and Tang JCO; Anti-cancer potential of traditional Chinese herbal medicines and microbial fermentation products. *Minerva Biotecnologica* 17:183-192, 2005.
79. Cheung F, Chui CH, Chan ASC, Lau FY, Cheng GYM, Wong RSM, Kok SHL, Teo ITN, Cheng CH and Tang JCO; Inhibition of proteasome activity in *Gleditsia sinensis* fruit extract-mediated apoptosis on human carcinoma cells. *Int J Mol Med* 2005 Nov. 16(5) P925-929.
80. Teo IT, Chui CH, Tang JC, Lau FY, Cheng GY, Wong RS, Kok SH, Cheng CH, Chan AS and Ho KP: Antiproliferation and induction of cell death of *Phaffia rhodozyma* (*Xanthophyllomyces dendrorhous*) extract fermented by brewer malt waste on breast cancer cells. *Int J Mol Med* 2005:16 (Nov 5) p931-936.
81. Lau FY, Chui CH, Gambari R, Kok SH, Kan KL, Cheng GYM, Wong RS, Teo IT, Cheng CH, Wan TS, Chan AS and Tang JC. Antiproliferative and apoptosis inducing activity of *Brucea javanica* extract on human carcinoma cells. *Int J Mol Med* 2005. 16 (6: December), 1157-1162.

82. Cheng M, Chan CW, Cheung RC, Bikkavilli RK, Zhao Q, Au SW, Chan PK, Lee SS, **Cheng G**, Ho WK, Cheung WT. Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11. *Biochem Biophys Res Commun*. 2005 Dec 23; 338(3): 1654-60.
83. Anthony M.H. Ho, Peter W. Dion, Claudia A.Y. Cheng, Manoj K. Karmakar, **Gregory Cheng**, Zhiyong Pend, Yu Wai Ng. A mathematical model for fresh frozen plasma transfusion strategies during major trauma resuscitation with ongoing hemorrhage. *J Can Chir Dec 05: Vol. 48 No. 6: 470-478*.
84. S.H.L. Kok, C.H. Chui, W.S. Lam, J Chen, J.C. Tang, F.Y. Lau, **G.Y.M. Cheng**, R.S. Wong and A.S. Chan. Induction of apoptosis on carcinoma cells by two synthetic cantharidin analogues. *Int J. Mol Med* 2006: 17(1, January) 151-157.
85. WONG Siu Ming Raymond; **Cheng Gregory**; CHAN Pui Ha Natalie; WONG Wai Shan and NG M.H. "Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency". *Am J Hematol* vol.81 no.1, pp.76. 2006.01.
86. Chui CH, Hau DK, Lau FY, **Cheng GY**, Wong RS, Gambari R, Kok SH, Lai KB, Teo IT, Leung TW, Higa T, Ke B, Tang JC, Fong DW, Chan AS. Apoptotic potential of the concentrated effective microorganism fermentation extract on human cancer cells. *Int J Mol Med*. 2006 Feb; 17(2):279-84.
87. Leung V, Leung V, Lui W, Chan T, Wong RS, **Cheng G**. Incidence of deep vein thrombosis in hospitalized Chinese medical patients is similar to that in western populations. *Thromb Res*. 2006; 118(6):763-4.
88. CHUI Chung Hin; CAMBARI R; LAU Fung Yi; **Cheng Gregory**; WONG Siu Ming Raymond; KOK S H; TANG J C; TEO I T; CHEUNG F; CHEUNG C H; HO K P; CHAN A S and WONG A. "In Vitro Anti-cancer Activity of a Novel Microbial Fermentation Product on Human Carcinomas". *Int J Mol Med* vol.17 no.4, p.675-679. 2006.04.
89. S.H.L. Kok, C.H. Chui, W.S. Lam, J Chen, F.Y. Lau, G.Y.M. Cheng, R.S.M. Wong, P.P.S. Lai, T.W.T. Leung, J.C.O. Tang and A.S.C. Chan. Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. *Int J. Mol Med* 2006: 17(May 5): 945-949.
90. S.H.L. Kok, C.H. Chui, W.S. Lam, J Chen, F.Y. Lau, R.S.M. Wong, G.Y.M. Cheng, W.K. Tang, C.H. Cheng, J.C.O. Tang and A.S.C. Chan. Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model. *Int. J Mol Med* 2006: 18 (2 August):375-379.
91. CH Chui, R Gambari, FY Lau, DKP Hau, RSM Wong, GYM Cheng, SHL Kok, T Higa, B Ke, ASC Chan, DWF Fong and JCO Tang. Antiangiogenic activity of a concentrated effective microorganism fermentation extract. (Hong Kong; PR China; Ferrara; Italy; Ryukyus; Okinawa; Japan) *Int J Mol Med* 2006:18; 975-979.
92. Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH. Management of Chinese patients

on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. *Br J Clin Pharmacol.* 2006 Nov; 62(5):601-9.

93. S.H.L. Kok, C.H. Chui, W.S. Lam, J Chen, F.Y. Lau, R.S.M. Wong, G.Y.M. Cheng, W.K. Tang, I.T.N. Teo, F. Cheung, C.H. Cheung, A.S.C. Chan and J.C.O. Tang (Hong Kong P.R. China). Apoptogenic activity of a synthetic cantharimide in leukaemia: Implication on its structural activity relationship. *Int J Mol Med* 2006; 18 (6: December); 1217-1221.
94. C.H. Chui, R.S.M. Wong, **G.Y.M. Cheng**, F.Y. Lau, S.H.L. Kok, C.H. Cheng, F. Cheung, W.K. Tang, I.T.N. Teo, A.S.C. Chan and J.C.O. Tang. Antiproliferative ability of a combination regimen of crocodile egg extract, wild radix ginseng and natural *Ganoderma lucidum* on acute myelogenous leukemia. *Oncology Reports* 2006: 16(6 December); 1313-1316.
95. S.H.L. Kok, C.H. Chui, W.S. Lam, J Chen, F.Y. Lau, R.S.M. Wong, **G.Y.M. Cheng**, P.B.S. Lai, T.W.T Leung, M.W.Y. Yu, J.C.O. Tang and A.S.C. Chan. Synthesis and Structure Evaluation of a Novel Cantharimide and its Cytotoxicity on SK-Hep-1 Hepatoma Cells. *Bioorganic & Medicinal Chemistry Letter* 2007 Mar 1; 17(5):1155-9.
96. Joyce HS. You, Zhong Zuo, Cindy M.Y. Lo, Limin Zhou, Hillary H.W. Yiu, Carrie T.S. Chau, Kai Chow Choi, David K.M. Choi, Raymond S.M. Wong, **Gregory Cheng**. Any Effect of CYP2C9 Variants on Warfarin Clearance in Chinese Patients? *Thromb Haemost* 2007; 97:866-868.
97. Kok SH, Gambari R, Chui CH, Lau FY, **Cheng GY**, Lai PB, Lam WS, Chan AS, Cheng CH, Teo IT, Yu MW, Tang JC, Cheung F, Wong RS.

Paradoxical proliferative potential of iron (II) sulphate on cancer cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. *Int J Mol Med.* 2007 Jun; 19(6):971-5.
98. Bussel J. B., **Cheng G.**, Saleh M.N., Psaiia B., Kovaleva L., Meddeb B., Kloczko J., Hassani H., Mayer B., Stone N.L., Arning M., Provan D., Jenkins J.M. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. *NEJM* 2007 Nov; 357: 2237-47.
99. Wong Siu Ming Raymond; Cheng Chi Keung; Chan Pui Ha Natalie; Cheng Suk Hang; Wong Wai Shan; Lau Kin Mang; **Cheng G** and Ng Heung Ling Margaret. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia". *British Journal of Haematology* vol.141 no.6, pp.902-904. 2008.04.10
100. You Hoi Sze Joyce; **Cheng G** and Chan Yan Keung Thomas. "Comparison of a clinical pharmacist-managed anticoagulation service with routine medical care: impact on clinical outcomes and health care costs". *Hong Kong Medical Journal Supplement* 3. vol.14 no.3,

pp.23-27. Hong Kong SAR: Hong Kong Academy of Medicine Press, 2008.06.

101. Chan Sau Hing; Lam Kim Hung; Chui Chung Hin; Gambari Roberto; Yuen Chun Wah Marcus; Wong Siu Ming Raymond; **Cheng Gregory**; Lau Fung Yi; AU Yiu Kwok; Cheng Chor Hing; Lai Bo San Paul; Kan Chi Wai; Kok Hon Lung Stanton; Tang Cheuk On Johnny and Chan Sun Chi Albert. The preparation and in vitro antiproliferative activity of phthalimide based ketones on MDAMB-231 and SKHep-1 human carcinoma cell lines. *European Journal of Medicinal Chemistry Elsevier*, 2008.11.05.
102. Kok Hon Lung Stanton; Wong Siu Ming Raymond; Gambari Roberto; Kok Hon Lung Stanton; Cheung Filly; Lam Wing Sze; Lau Fung Yi; **Cheng Gregory**; Cheng Chor Hing; Lam Kim Hung; Chan Sau Hing; Tang Cheuk On Johnny; Chui Chung Hin and Ho Kwok Ping. "In vitro cytotoxicity of (-)-EGCG octaacetate on MDAMB-231 and SKHep-1 human carcinoma cells: a pharmacological consideration on prodrug design.". *International Journal of Molecular Medicine* vol.22 no.6, pp.841-845. 2008.12
103. Lu Guo Liang; Ho Cheuk Lam; Wang Qiwei; Wong Wai Yeung; Chui Chung Hin; Wong Siu Ming Raymond; Gambari Roberto; Lau Fung Yi; Yuen Chun Wah Marcus; Tong See Wai; Chan Kit Wah Andrew; Tang Cheuk On Jonny; Ho Kwok Ping and **Cheng Gregory**. "Synthesis and Characterization of Some Metal Complexes of 4,5-Diazafluoren-9-one and their Biological Effects on Human Carcinoma Cells". *Australian Journal of Chemistry* vol.61 no.12, pp.975 980. 2008.12.10.
104. Bussel B J; Provan D; Shamsi T; **Cheng Gregory**; Psaila B; Kovaleva L; Salama A; Jenkins M J; Roychowdhury D; Mayer B; Stone N and Arning M. "Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.". *Lancet* vol.373 no.9664, pp.641-8. 2009.02.21.
105. You Hoi Sze Joyce; Tsui Kit Nga; Wong Siu Ming Raymond and **Cheng Gregory**. "Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy". *Clinical Pharmacology and Therapeutics* Advanced online publication:1-8. United States of America: Nature Publishing Group, 2009.07.01.
106. Wang Qiwei; Yuen Chun Wah Marcus; Lu Guo Liang; Ho Cheuk Lam; Zhou Gui Juang; Keung Oi Mei; Lam Kim Hung; Gambari Roberto; Tao Xiao Ming; Wong Siu Ming Raymond; Tong See Wai; Chan Kit Wah; Lau Fung Yi; Cheung Filly; **Cheng Yin Ming Gregory**; Chui Chung Hin; Wong
-4,5-diazafluorene Derivatives and Their Structure Activity Relationships Toward Human Carcinoma Cell Lines" *ChemMedChem*. 2010 Apr 6;5(4):559-66.

107. Lam KH, Gambari R, Yuen MC, Kan CW, Chan P, Xu L, Tang W, Chui CH, **Cheng GY**, Wong RS, Lau FY, Tong CS, Chan AK, Lai PB, Kok SH, Cheng CH, Chan AS, Tang JC. The preparation of 2,6-disubstituted pyridinyl phosphine oxides as novel anti-cancer agents. *Bioorg Med Chem Lett*. 2009 Apr 15;19(8):2266-9. Epub 2009 Feb 27 PMID: 19321340
108. Hau DK, Gambari R, Wong RS, Yuen MC, **Cheng GY**, Tong CS, Zhu GY, Leung AK, Lai PB, Lau FY, Chan AK, Wong WY, Kok SH, Cheng CH, Kan CW, Chan AS, Chui CH, Tang JC, Fong DW. Phyllanthus urinaria extract attenuates acetaminophen induced hepatotoxicity: involvement of cytochrome P450 CYP2E1. *Phytomedicine*. 2009 Aug; 16(8):751-60. Epub 2009 Apr 21.
109. Chui CH, Wong RS, Gambari R, **Cheng GY**, Yuen MC, Chan KW, Tong SW, Lau FY, Lai PB, Lam KH, Ho CL, Kan CW, Leung KS, Wong WY. Antitumor activity of diethynylfluorene derivatives of gold (I). *Bioorg Med Chem*. 2009 Dec 1; 17(23):7872-7. Epub 2009 Oct 21.
110. Chui CH, Wang Q, Chow WC, Yuen MC, Wong KL, Kwok WM, **Cheng GY**, Wong RS, Tong SW, Chan KW, Lau FY, Lai PB, Lam KH, Fabbri E, Tao XM, Gambari R, Wong WY. 5-(Dimethylamino)-N-(4-ethynylphenyl)-1-naphthalenesulfonamide as a novel bifunctional antitumor agent and two-photon induced bio-imaging probe. *Chem Commun (Camb)*. 2010 May 28;46(20):3538-40. Epub 2010 Apr 9.
111. Zuo Z, **Wo SK**, Lo CM, Zhou L, Cheng G, You JH. Simultaneous measurements of S warfarin, R warfarin, S-7 hydroxy warfarin and R-7 hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal* 2010 Jun 5;52(2):305-10. Epub 2010 Jan 18.
112. Cheng SY, Yuen MC, Lam PL, Gambari R, Wong RS, **Cheng GY**, Lai PB, Tong SW, Chan KW, Lau FY, Kok SH, Lam KH, Chui CH. Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules. *Bioorg Med Chem Lett*. 2010 Jul 15;20(14):4147-51. Epub 2010 Jun 9.
113. Hau DK, Wong RS, **Cheng GY**, Wong WY, Tong SW, Chan KW, Leung AK, Zhu GY, Lai PB, Lau FY, Chui CH, Gambari R, Fong DW. Novel use of silymarin as delayed therapy for acetaminophen-induced acute hepatic injury. *Forsch Komplementmed*. 2010;17(4):209-13. Epub 2010 Aug 3.
114. Lam KH, Chui CH, Gambari R, Wong RS, **Cheng GY**, Lau FY, Lai PB, Tong SW, Chan KW, Wong WY, Chan AS, Tang JC. The preparation of bi-functional organophosphine oxides as potential antitumor agents. *Eur J Med Chem*. 2010 Nov;45(11):5527-30. Epub 2010 Aug 24.
115. Hau DK, Zhu GY, Leung AK, Wong RS, **Cheng GY**, Lai PB, Tong SW, Lau FY, Chan KW,

Wong WY, Lam KH, Cheng CH, Cheung F, Chui CH, Gambari R, Fong DW. In vitro anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. *Phytomedicine*. 2010 Dec 15; 18(1):11-5.

116. **Gregory Cheng**, Mansoor N. Saleh, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole L. Stone, James B. Bussel. Eltrombopag for the Management of Chronic Immune Thrombocytopenia: a 6-month, Randomised, Phase III Study (RAISE). *Lancet*. 2011 Jan 29;377(9763):393-402. Epub 2010 Aug 23.
117. Joyce H.S. You, Raymond S.M. Wong, Mary M.Y. Waye, Yawei Mu, Cadmon K. Lim, Kai-chow Choi, **Gregory Cheng**. Warfarin Dosing Algorithm using Clinical, Demographic and Pharmacogenetic Data from Chinese Patients. *J Thromb Thrombolysis*. 2011 Jan;31(1):113-8.
118. **Cheng G**, Chan C, Liu YT, Choy YF, Wong MM, Yeung PK, Ng KL, Tsang LS, Wong SM. Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT Prophylaxis. *Thrombosis*; 2011:629383. Epub 2011 Feb 15.
119. **Cheng G**. Eltrombopag for treatment of ITP. *Expert Rev Hematol*. 2011 Jun;4(3):261-9.
120. **Cheng G**, Saleh MN, Marcher C, Aivado M, Bussel JB..Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase3 study. *Response Letter Lancet* 2011Jun 4; 377:1919-20
121. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, **Cheng G**, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. *Blood* 2011; Nov 22. [Epub ahead of print]
122. Lam PL, Lee KK, Wong RS, Cheng GY, Cheng SY, Yuen MC, Lam KH, Gambari R, Kok SH, Chui CH. Development of hydrocortisone succinic acid/and 5-fluorouracil/chitosan microcapsules for oral and topical drug deliveries. *Bioorg Med Chem Lett*. 2012 May1; 22(9):3213-8. Epub 2012 Mar 13.
123. Tam WH, Ng MH, Yiu AK, Lau KM, Cheng GY, Li CY. Thrombophilia among Chinese women with venous thromboembolism during pregnancy. *Gynecol Obstet Invest*. 2012;73(3):183-8. Epub 2012 Mar 6.
124. Powell JS, Josephson NC, Quon D, Ragni MV, **Cheng G**, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. *Blood* 2012;119(13):3031-7
125. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill

patients. *N Engl J Med.* 2011 Dec 8;365(23):2167-77. Epub 2011 Nov 13.

126. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med.* 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.
127. Cheng G. Eltrombopag Thrombopoietin Receptor Agonist for Treatment of Immune Thrombocytopenia: Current and Future Considerations. *Clinical Medicine Reviews in Vascular Health* 2012;4 9-18
128. Cheng G. Eltrombopag: a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. *Therapeutic Advances in Hematology* 2012;3(3) 3:155-164
129. Joyce H. S. You, Kia K. N. Tsui¹, Raymond S. M. Wong, Gregory Cheng. Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation. *PLoS One.* 2012;7(6): e39640. doi: 10.1371/journal.pone.0039640
130. Lam KH, Lee KK, Gambari R, Wong RS, Cheng GY, Tong SW, Chan KW, Lau FY, Lai PB, Wong WY, Chan AS, Kok SH, Tang JC, Chui CH. Preparation of Galipea officinalis Hancock type tetrahydroquinoline alkaloid analogues as anti-tumour agents. *Phytomedicine.* 2012 Nov 1. doi:pii: S0944-7113(12)00362-5. 10.1016/j.phymed.2012.09.026. [Epub ahead of print
131. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia (ITP): results of the long-term, open-label EXTEND study. *Blood.* 2012;121(3):537-45 Nov 20.
132. Lam PL, Kok SH, Ho YW, Wong RS, Cheng GY, Cheng CH, Lam KH, Gambari R, Lee KK, **Chui CH.** A novel green gelatin-agar microencapsulation system with *P. urinaria* as an improved anti-*A niger* model. *Carbohydr Polym.* 2013 Jan 30; 92(1):877-80. doi: 10.1016/j.carbpol.2012.09.080. Epub 2012 Oct 13.
133. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou T, Feigert J, Yeh S-P, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino Fa Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. *Lancet Haematol.* 2015 Oct;2(10): e417-26. doi:10.1016/S2352-3026(15)00149-0.

134. Cheng G. Will thrombopoietin receptor agonist become a treatment option for pediatric chronic ITP in the future? *Clinical Investigation* 2015; 5(3): 287-296
135. Lam KH, Lee KK, Kok SH, Wong RS, Lau FY, Cheng GY, Wong WY, Tong SW, Chan KW, Chan RY, Tang JC, Cheng CH, Hau DK, Bian ZX, Gambari R, Chui CH. Antiangiogenic activity of 2-formyl-8-hydroxy-quinolinium chloride. *Biomed Pharmacother.* 2016 May; 80:145-50. doi: 10.1016/j.biopha.2016.03.014
136. Wang QW, Lam PL, Wong RS, Cheng GY, Lam KH, Bian ZX, Ho CL, Feng YH, Gambari R, Lo YH, Wong WY, Chui CH. Synthesis of platinum(II) and palladium(II) complexes with 9,9-dihexyl-4,5-diazafluorene and their in vivo antitumour activity against Hep3B xenografted mice. *Eur J Med Chem.* 2016 Nov 29;124:537-543. doi: 10.1016/j.ejmech.2016.08.033
137. Chao Pui I, Cheng Gregory, Zhang Lunqing, Lo Iek Long, Chan Hong Tou, Cheong Tak Hong: Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients. *J Lung Health Dis* (2017) 1(1): 16-24
138. Lam PL Lee KKH, Wong RSM, Cheng GYM Bian ZX, Chui CH Gambari R. Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns. *Crit Rev Microbiol.* 2018 Feb;44(1):40-78. doi: 10.1080/1040841X.2017.1313811. Epub 2017 Apr 19. Review.
139. Tsui NBY, Cheng G, Chung T, Lam CWK, Yee A, Chung PKC, Kwan TK, Ko E, He D, Wong WT, Lau JYN, Lau LT, Fok M. Population-Wide Genetic Risk Prediction of Complex Diseases: A Pilot Feasibility Study in Macau Population for Precision Public Healthcare Planning. *Sci Rep.* 2018 Jan 30;8(1):1853. doi: 10.1038/s41598-017-19017-y

140. Zhang LQ, Zhang MJ, Du X, Cheng YF, Cheng G: Safety and efficacy of eltrombopag plus pulsed dexamethasone as first line therapy for Immune Thrombocytopenia (ITP). *British Journal of Hematology* January 2020 <https://doi.org/10.1111/bjh.16327>
141. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol.* 2020 Apr 8. pii: S0168-8278(20)30206-3. doi: 10.1016/j.jhep.2020.03.044.
142. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease'. *J Hepatol.* 2020 May 5. pii: S0168-8278(20)30285-3. doi: 10.1016/j.jhep.2020.04.039
143. Liu H, He X, Wang Y, Zhou S, Zhang D, Zhu J, He Q, Zhu Z, Li G, Sun L, Wang J, Cheng G, Liu Z, Lau G. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. *Hepatol Int.* 2020 Apr 10. doi: 10.1007/s12072-020-10043-z
144. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, Chen G, Cheng G, Wang Y, Bi J, Tan L, Lau G, Qin E. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. *Clin Infect Dis.* 2020 Apr 9. pii: ciaa414. doi: 10.1093/cid/ciaa414
145. APASL Covid-19 Task Force, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. *Hepatology International* 2020 May <https://doi.org/10.1007/s12072-020-10054-w>
146. Ji D, Zhang D, Yang T, Mu J, Zhao P, Xu J, Li C, Cheng G, Wang Y, Chen Z, Qin E, Lau G. Effect of COVID-19 on patients with compensated chronic liver diseases. *Hepatology International* 2020 May <https://doi.org/10.1007/s12072-020-10058-6>
147. Ji D, Qin E, Zhang D, Cheng G, Lau G. Reply to Grifoni et al The CALL Score for Predicting Outcomes in Patients With COVID-19. *Clinical Infectious Diseases*, <https://doi.org/10.1093/cid/ciaa699>
148. Zhang MJ, Zhang L, Cheng G. Achieving Treatment Free Prolonged Response in ITP patients Treated with Thrombopoietin Receptor Agonists (TPO-RAs) *J Clin Res Med*, 2020 Volume 3(2): 1-2.

149. Shao F, Lyu X, Miao K, Xie L, Wang H, Xiao H, Li J, Chen Q, Ding R, Chen P, Xing F, Zhang X, Luo G, Zhu W, Cheng G, et al Enhanced Protein Damage Clearance Induces Broad Drug Resistance in M

11 October 2020

<https://doi.org/10.1002/adv.202001914>

150. Ji D, Qin E, Zhang D, Cheng G, Lau G. Reply to Author. The inherent problems with the generalizability of the CALL score: towards reliable clinical prediction models for COVID-19. *Clinical Infectious Diseases*, ciaa1568, <https://doi.org/10.1093/cid/>

151. Ji D, Cheng G, Lau G. Reply to: is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression-The debate *J Hepatol*. 2020 October 29
<https://doi.org/10.1016/j.jhep.2020.10.020>.

152. Dong Ji, Mingjie Zhang, Enqiang Qin, Lunqing Zhang, Jing Xu, Yudong Wang, Gregory Cheng, Feng Wang, George Lau: Obesity, Diabetes, Non-alcoholic Fatty Liver Disease and Metabolic Dysfunction Associated Fatty Liver Disease are Proinflammatory Hypercoagulable States associated with Severe Disease and Thrombosis in Covid-19 *Metabolism* 2020; 108:154437
<https://doi.org/10.1016/j.metabol.2020.154437>

153. Dong Ji, Guo-feng Chen, Xiao-xia Niu, Mingjie Zhang, Cheng Wang, Qing Shao, Vanessa Wu, Yudong Wang, Gregory Cheng, Selwyn J. Hurwitz, Raymond F. Schinazi, George Lau, Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. *Metabolism Open* Vol 10, 2021 <https://doi.org/10.1016/j.metop.2021.100090>.

154. George Lau, Ming-Lung Yu, Grace Wong, Alexander Thompson, Hasmik Ghazianian, Jin-Lin Hou, Teerha Piratvisuth, Ji-Dong Jia, Masashi Mizokami, Gregory Cheng et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy-2021. *Hepatology International* 2021 July <https://doi.org/10.1007/s12072-021-10293-7>

155. Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. *Glob Health Med*. 2021 Oct 31;3(5):276-282. doi: 10.35772/ghm.2021.01075. PMID: 34782869; PMCID: PMC8562093.

Textbook

Textbook of Clinical Medicine for Asia, (Edited by JY Sung, PKT Li, JE Sanderson & J Woo). Chapter 6.3 Haemolytic Anemia, Chapter 6.7 Transfusion Medicine and Chapter 6.8 Haemostasis, Thrombosis and Coagulopathy

Essential Internal Medicine. (Edited by Joseph JY Sung, Ji yao Wang, Ti Shen). Part 6 Haematological Disease Bleeding Disorder Part 1&2, 2009

